Unified neuro biomarker Cognision offers a unified platform, COGNISION360, that integrates EEG, ERP, PSG, eye tracking, wearables, cognitive assessments, and eCOA/ePRO/eObsRO for CNS clinical trials, representing a holistic data solution that can streamline decison-making and potentially open opportunities with pharmas and CROs seeking integrated neuro biomarker workflows.

FDA-cleared cloud system The COGNISION system is FDA-cleared and cloud-powered, highlighting regulatory readiness and scalable deployment, which can be positioned to clinicians and trial sponsors as a compliant, scalable option for neurocognitive biomarker assessment across sites.

Clinical trial focus Recent activity noting implementation in multiple clinical trials and a founding role in the EEG/ERP Biomarker Qualification Consortium signals relevance to CNS drug development and potential partnerships with pharmaceutical companies pursuing biomarker-driven CNS trials.

Sleep and cognition emphasis The platform’s expanded data types including PSG and sleep-related biomarkers align with growing interest in sleep-cognition links, offering cross-sell opportunities to organizations exploring dementia, concussion, and CNS disorders where sleep metrics add value.

Market positioning fit With a focus on neurocognitive biomarkers and a scalable, cloud-based solution in a market with competitors of varying scale, Cognision can target mid-sized CROs and biotech firms seeking cost-effective, integrated EEG/ERP solutions and turnkey trial data management to differentiate in CNS programs.